|Bid||3.3700 x 4000|
|Ask||3.4000 x 42300|
|Day's Range||3.0400 - 3.4100|
|52 Week Range||2.0900 - 13.7100|
|Beta (5Y Monthly)||1.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 44,000 shares of Akebia's common stock on February 26, 2021, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
During Q4, Akebia Therapeutics's (NASDAQ:AKBA) reported sales totaled $56.70 million. Despite a 47.01% in earnings, the company posted a loss of $85.40 million. In Q3, Akebia Therapeutics brought in $59.99 million in sales but lost $58.09 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Akebia Therapeutics posted an ROCE of -0.34%. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. View more earnings on AKBA Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders. In Akebia Therapeutics's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions. Q4 Earnings Recap Akebia Therapeutics reported Q4 earnings per share at $-0.6/share, which did not meet analyst predictions of $-0.4/share. See more from BenzingaClick here for options trades from Benzinga12 Health Care Stocks Moving In Thursday's Intraday Session© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Akebia Therapeutics' total revenue of $56.7 million for its fourth quarter, ending Dec. 31, beat the consensus analyst estimate, which was $51.16 million. On the bottom line, Akebia Therapeutics reported a net loss of $87 million -- $0.60 per share -- compared to the net loss and net loss per share of $94.5 million and $0.79 respectively that it recorded during the fourth quarter of the previous fiscal year. On average, analysts expected the company's net loss per share to be $0.40.